US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by ZyVersa Therapeutics
< Previous
1
2
3
Next >
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
November 30, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
November 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
November 09, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing
November 01, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
October 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
October 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
October 04, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
September 27, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
September 22, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
September 12, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
August 21, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
July 24, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
July 17, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
July 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
July 10, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
July 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
June 28, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
June 20, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
June 13, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
June 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
May 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors
May 19, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
May 15, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
May 12, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
May 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
May 09, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
May 04, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
< Previous
1
2
3
Next >
